National Immunisation Program schedule vaccines Vaccine safety data Main navigation COVID-19 vaccines Influenza vaccines Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines 2 months schedule point 4 months schedule point 6 months schedule point 12 months schedule point 18 months schedule point 4 years schedule point 12-13 years schedule point 14-16 years schedule point Pregnant people schedule point Older adults pneumococcal schedule point Older adults zoster (shingles) schedule point Nirsevimab RSV vaccines Shingrix® The National Immunisation Program (NIP) schedule is a series of immunisations given at specific times throughout your life. AusVaxSafety is conducting active vaccine safety surveillance of all NIP schedule vaccines used in Australia to ensure their ongoing safety. This surveillance has been undertaken by AusVaxSafety on a continuous basis since 2019. Over this time, the analysis has remained constant and not identified any safety concerns.In April 2022, the vaccine safety survey used for active surveillance of vaccines on the NIP was updated to replicate the vaccine safety survey used for COVID-19 and seasonal influenza vaccine surveillance to allow for better comparison across all vaccines monitored. Data displayed on this page show analysis of the new survey. Reassuringly, data from the new vaccine safety survey are comparable to the rates reported in the previous survey. This page reflects data from people who received a vaccine at a participating clinic and responded to an AusVaxSafety SMS a few days after vaccination. It does not include data from every person who received a vaccine. The graphic below will be updated on a quarterly basis.Latest NIP schedule vaccine safety dataClick on the tiles below to view AusVaxSafety vaccine safety data for all NIP schedule points. 2 months schedule point View vaccine safety data for the 2 months schedule point 4 months schedule point View vaccine safety data for the 4 months schedule point 6 months schedule point View vaccine safety data for the 6 months schedule point 12 months schedule point View vaccine safety data for the 12 months schedule point 18 months schedule point View vaccine safety data for the 18 months schedule point 4 years schedule point View vaccine safety data for the 4 years schedule point 12–13 years schedule point View vaccine safety data for the 12-13 years schedule point 14-16 years schedule point View vaccine safety data for the 14-16 years schedule point Pregnant people schedule point View vaccine safety data for pregnant people schedule point Older adults pneumococcal schedule point View vaccine safety data for the Older adults pneumococcal schedule point schedule point Older adults zoster (shingles) schedule point View vaccine safety data for the older adults zoster (shingles) schedule point schedule point Vaccine safety data Main navigation COVID-19 vaccines Influenza vaccines Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines 2 months schedule point 4 months schedule point 6 months schedule point 12 months schedule point 18 months schedule point 4 years schedule point 12-13 years schedule point 14-16 years schedule point Pregnant people schedule point Older adults pneumococcal schedule point Older adults zoster (shingles) schedule point Nirsevimab RSV vaccines Shingrix® News & events All news & events 08 November 2024 | News Enhanced National Immunisation Program vaccine safety data now available 23 October 2024 | News AusVaxSafety study affirms short-term safety profile of Moderna and Novavax COVID-19 vaccine priming doses 01 October 2024 | News AusVaxSafety marks a decade of progress in vaccine safety 12 September 2024 | News AusVaxSafety surveillance of 2024 seasonal flu vaccines concludes with no safety issues identified